Euro
USD
British Pound
NULL
Product Description
The spike (S) glycoprotein of coronaviruses mediates entry into receptor-expressing host cells and plays the most important role in viral attachment, fusion, and entry; therefore, it serves as an important target for monoclonal antibodies, entry inhibitors, and vaccines. The S protein has two domains S1 and S2, where S1 facilitates initial binding to the receptor and the S2 domain drives membrane fusion and eventual entry of the virus. Within the S1 protein, the highly conserved receptor-binding domain (RBD) expresses a high affinity for the Angiotensin converting enzyme 2 receptor (ACE2). The original biosimilar was designed to target the RBD at different epitopes in tandem with Anti-SARS-CoV-2 RBD-01 (Cat. No. A2353) in order to reduce drug resistance during COVID-19 therapeutic trials.
Biovision | A2354 | Anti-SARS-CoV-2 RBD-02 Humanized Antibody DataSheet
Antibody Target: Receptor binding domain of SARS-CoV-2 spike protein
Target Alternative Name: COVID-19 Spike RBD protein; 2019-nCoV Spike RBD protein
Tag Line: A humanized monoclonal antibody targeting the SARS-CoV-2 spike protein receptor binding domain, in tandem with Anti-SARS-CoV-2 RBD-01
Category: GM-CSF
Host: XtenCHO cells
Isotype: Humanized IgG1
Species Reactivities: SARS-CoV-2
Immunogen Sequence: Receptor binding domain of SARS-CoV-2 spike protein
Accession #:
Gene ID:
Appearance: Liquid
Form: Humanized IgG1
Concentration:
Formulation: In PBS, pH 7.5
Purification:
Application: ELISA
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: TRUE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
